Indonesia is set to host its first-ever plasma fractionation plant in Karawang, West Java, which is expected to become the largest facility of its kind in Southeast Asia. This milestone represents a significant step toward operational readiness while strengthening the country’s healthcare resilience.
Construction of the SK Plasma Fractionation Plant has reached 98.72 percent completion and is expected to be finalized, with operations beginning, in February 2026. The long-awaited facility has an annual production capacity of 600,000 liters of plasma and is scheduled to begin full-scale production in 2026.
The 4.9-hectare plant is owned by PT SK Plasma Core Indonesia, a joint venture between South Korea’s SK Plasma and the Indonesia Investment Authority (INA). The facility was developed following a ministerial decree issued in December 2023 appointing the company as Indonesia’s official plasma fractionator.
INA CEO Ridha DM Wirakusumah expressed enthusiasm for the establishment of the plasma fractionation plant, noting that Indonesia had aspired to own such a facility for the past 17 years.
The ambition was finally realized in 2023 when SK Plasma and INA, with government support, agreed to jointly develop the project.
Indonesia, through the Indonesian Red Cross (PMI), collects approximately 4 million blood bags annually. “Only the erythrocytes are used, while the plasma and white blood cells (leukocytes) are discarded,” Ridha said.